BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
School of Medicine, Medical Sciences and Nutrition. Room 4.015. Polwarth Bulding. Foresterhill. Aberdeen. AB25 2ZD
and
Centre for Genome Enabled Biology and Medicine. Room G17. 23 St Machar Drive. Old Aberdeen. Aberdeen. AB24 3RY.
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Elaina Collie-Duguid was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. Her time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to begin a PhD in molecular and cellular biology at the Rowett Research Institute. In 1996, Dr Collie-Duguid took up post as a post-doctoral scientist in the Department of Medicine and Therapeutics at the University of Aberdeen and she now heads a Cancer Medicine research group with a particular focus on breast cancer within the Cancer Biomedicine programme.
Dr Collie-Duguid manages the Centre for Genome Enabled Biology and Medicine (CGEBM) at the University of Aberdeen. CGEBM provides strategic direction and coordinated management of the University of Aberdeen’s genomics facilities and facilitates genomics enabled interdisciplinary research by provision of specialised expertise, infrastructure, training, a focal point for collaboration and information exchange and genomics services to the research community. CGEBM provides specialist services in next generation sequencing (NGS), microarrays, bioinformatics and biostatistics. CGEBM helps to drive genome focused research forward by developing and exploiting modern genomic technologies to accelerate discovery of novel approaches to improve human health, the environment and agriculture within the diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen.
External Memberships
Scientific Member of the Experimental and Translational Medicine Research Committee of the Chief Scientist Office, 2009-2014
Scientific Member of the Biomedical and Therapeutics Research Committee of the Chief Scientist Office, 2005-2009.
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
Dr Collie-Duguid teaches on level 5 courses MB5021 Bioinformatics, MT5003 Drug Metabolism and Toxicology, and MT5515 Research Methods, level 4 PA4302 Molecular Toxicology, level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and Intercalated BSc MB ChB teaching in Genetic variation and Bioinformatics, and provides research project supervision to level 5 MSc students in the field of genomics.
- Publications
-
Page 3 of 7 Results 21 to 30 of 64
SerpinB3, a biomarker of taxane benefit in breast cancer
1st British Breast Cancer Research Conference, pp. 13Contributions to Journals: AbstractsAberdeen Microarray and PET in Optimising Oesophagogastric Cancer Response-1 (AMPETOOR-1). Preliminary Results: Preliminary Results
Annals of Oncology, vol. 21, pp. 43Contributions to Journals: ArticlesAPRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling
BMC Cancer, vol. 9, pp. 434Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1186/1471-2407-9-434
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/3027/1/1471_2407_9_434_1_.pdf
Balancing Inflammatory, Lipid, and Xenobiotic Signaling Pathways by VSL#3, a Biotherapeutic Agent, in the Treatment of Inflammatory Bowel Disease
Inflammatory Bowel Diseases, vol. 15, no. 11, pp. 1721-1736Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/ibd.20999
Gene expression analysis of human fetal ovarian primordial follicle formation
Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 4, pp. 1427-1435Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1210/jc.2008-2619
Growth hormone in vascular pathology: Neovascularisation and expression of receptors is associated with cellular proliferation
Anticancer Research, vol. 28, no. 2B, pp. 1439Contributions to Journals: ArticlesDecreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro
Nuclear Medicine and Biology, vol. 34, no. 8, pp. 955-960Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.nucmedbio.2007.07.007
Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks
Cancer Chemotherapy and Pharmacology, vol. 59, no. 6, pp. 839-845Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00280-006-0384-5
Cancer Therapy Prognosis and Target
Patents: PatentsPregnane X Receptor Activators Inhibit Human Hepatic Stellate Cell Trans-Differentiation in Vitro
Gastroenterology, vol. 131, no. 1, pp. 194-209Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1053/j.gastro.2006.04.012